Fundraising Fox
Embolx
Sunnyvale, US · Founded 2013 · 2 known investors
Find your way into Embolx
Sign up to see every warm intro you have to Embolx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Embolx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Embolx is a commercial-stage medical device company developing microcatheters for arterial embolization procedures used to treat conditions such as cancerous tumors, benign prostatic hyperplasia, and uterine fibroids. Its Sniper balloon occlusion microcatheter controls blood flow pressure to direct embolic delivery to target tissue while protecting surrounding tissue.
Founders & leadership
RJ
Robert J.J. de NeveExecutive
MA
Michael AllenPresident & CEOMichael Allen is President and CEO of Embolx, a commercial-stage medical device company developing microcatheters for arterial embolization. He previously held CEO positions at Xlumena and Metrika (acquired by Bayer Healthcare in 2006), led R&D at Chemtrack, and worked as an R&D scientist at Syva (Syntex), and holds a degree in biochemistry from UC Berkeley with multiple patents and publications.
NG
NORMAN GITISNamed on SEC filing
PR
Paul RoganNamed on SEC filing
TX
TIANHONG XUNamed on SEC filing
TB
TOM BRETONManager of Research & Development
ML
MICHAEL LINDirector of Finance
Investors · 2
Also in the syndicate · 1
PAID, Inc.
Reported raises · per SEC filings
Form D private placements$2.1M disclosed across 4 rounds · 2014–2022
▶$1.6MraisedNov 2022 · 5 investors · OtherRule 506(b)
▶$1.6MraisedNov 2022 · 5 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- NORMAN GITISDirector
- PAUL ROGANDirector
- TOM BRETONExecutive Officer
- FRANK GRILLODirector
- MICHAEL ALLENExecutive Officer, Director
- TIANHONG XUDirector
- MICHAEL LINExecutive Officer
- Offering amount
- $1.6M
- Amount sold
- $1.6M
- Sales commissions
- $130.3K
- Placement agents
- Revere Securities LLC
- First sale
- Oct 2022
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$250KraisedMay 2014 · 1 investors · OtherRule 506(b)
▶$250KraisedMay 2014 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Michael P. AllenExecutive Officer, Director
- Paul F. RoganDirector
- Robert J.J. de NeveExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $250K
- First sale
- May 2014
- Incorporated
- Corporation, California, 2013
- Federal exemptions
- 06b, 04.3, 4a5
▶$662raisedMar 2014 · 3 investors · OtherRule 506(b)
▶$662raisedMar 2014 · 3 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Michael P. AllenExecutive Officer, Director
- Paul F. RoganDirector
- Robert J.J. de NeveExecutive Officer, Director
- Offering amount
- $662
- Amount sold
- $662
- First sale
- Feb 2014
- Incorporated
- Corporation, California, 2013
- Federal exemptions
- 06b, 04.3, 4a5
▶$250KraisedMar 2014 · 1 investors · OtherRule 506(b)
▶$250KraisedMar 2014 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Michael P. AllenExecutive Officer, Director
- Robert J.J. de NeveExecutive Officer, Director
- Paul F. RoganDirector
- Offering amount
- $250K
- Amount sold
- $250K
- First sale
- Feb 2014
- Incorporated
- Corporation, California, 2013
- Federal exemptions
- 06b, 04.3, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Boston ScientificBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Merit MedicalMerit Medical Systems designs, develops, manufactures and markets medical devices for interventional and diagnostic procedures. The company serves healthcare providers and clinical practitioners in the medical device industry.
Rf SurgicalMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
BDBD is a global medical technology company developing devices, systems, and solutions for medication administration, diagnostics, connected care, biopharmaceutical manufacturing, and interventional procedures. The company serves healthcare providers, laboratories, and biopharmaceutical manufacturers across diagnostics, drug delivery, surgical care, and patient monitoring.
Companies working in the same space as Embolx.
Frequently asked questions
- What does Embolx do?
- Embolx is a commercial-stage medical device company developing microcatheters for arterial embolization procedures used to treat conditions such as cancerous tumors, benign prostatic hyperplasia, and uterine fibroids. Its Sniper balloon occlusion microcatheter controls blood flow pressure to direct embolic delivery to target tissue while protecting surrounding tissue.
- Who are Embolx's investors?
- Embolx's investors include BayMed Venture Partners.
- How much funding has Embolx raised?
- Embolx has disclosed $2.1M raised across 4 rounds.
- Where is Embolx headquartered?
- Embolx is headquartered in Sunnyvale, US.